Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
0(0%)
Results Posted
92%(12 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
2
14%
Ph phase_3
11
79%
Ph phase_4
1
7%

Phase Distribution

2

Early Stage

0

Mid Stage

12

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 3Large-scale testing
11(78.6%)
Phase 4Post-market surveillance
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(13)
Terminated(1)

Detailed Status

Completed13
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 311 (78.6%)
Phase 41 (7.1%)

Trials by Status

terminated17%
completed1393%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_3

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
completedphase_3

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
completedphase_3

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
completedphase_3

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
completedphase_3

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT03213457Phase 3

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Completed
NCT03751124Phase 3

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT03412890Phase 3

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT03654274Phase 3

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Completed
NCT03103087Phase 3

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT03049735Phase 3

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT02691494Phase 3

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Completed
NCT02925494Phase 3

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
NCT03204331Phase 3

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Completed
NCT03204318Phase 3

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Completed
NCT02654054Phase 3

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Completed
NCT02693002Phase 4

Estrogen Diastolic Heart Failure

Terminated
NCT01157182Phase 1

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions

Completed
NCT01181726Phase 1

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14